Ligand Pharmaceuticals
LGND
Market cap $1.89B

103.24 USD

+0.27

0.26%

At close Oct 9, 4:00 PM EDT

After hours

103.24

+0.00

0.00%

1 day

0.26%

5 days

2.18%

1 month

0.45%

3 months

12.57%

6 months

26.67%

Year to date

42.77%

1 year

75.46%

5 years

1.98%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

848% more call options, than puts

Call options by funds: $6.3M | Put options by funds: $665K

100% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]

45% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 29

20% more capital invested

Capital invested by funds: $1.22B [Q1] → $1.45B (+$238M) [Q2]

14% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 72

6% more funds holding

Funds holding: 219 [Q1] → 232 (+13) [Q2]

2.01% more ownership

Funds ownership: 94.04% [Q1] → 96.05% (+2.01%) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$110

7%

upside

Avg. target

$131

27%

upside

High target

$144

39%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Leland Gershell 52% 1-year accuracy 23 / 44 met price target	31%upside $135	Outperform Initiated	3 Oct 2024
Benchmark Robert Wasserman 58% 1-year accuracy 25 / 43 met price target	7%upside $110	Buy Maintained	12 Aug 2024
RBC Capital Douglas Miehm 75% 1-year accuracy 3 / 4 met price target	26%upside $130	Outperform Reiterated	12 Aug 2024
HC Wainwright & Co. Joseph Pantginis 57% 1-year accuracy 13 / 23 met price target	39%upside $144	Buy Reiterated	8 Aug 2024
RBC Capital Douglas Miehm 75% 1-year accuracy 3 / 4 met price target	26%upside $130	Outperform Reiterated	7 Aug 2024

See Analyst Rankings

Financial journalist opinion

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI. FILSPARI was granted accelerated approval in.

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Global CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Forecast 2024-2030" report has been added to ResearchAndMarkets.com's offering. The CD40 Ligand Market size was estimated at USD 697.21 million in 2023, USD 734.50 million in 2024, and is expected to grow at a CAGR of 5.47% to reachUSD 1.01 billion by 2030. This makes it intensely relevant in developing treatments for immune disorders, specific cancers, and autoimmune diseases. In therapeutic applications, CD40L-based treatments are crucial for managing conditions such as lymphoma and leukemia, potentially extending to some solid tumors by boosting the immune system's ability to fight cancer cells. Furthermore, CD40L's function in autoimmune disorders suggests its modulation could lessen disease severity in ailments such as systemic lupus erythematosus and rheumatoid arthritis. In vaccine development, enhancing immune responses through CD40L could significantly improve vaccine efficacy against various diseases.

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should conta.

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Investors Business Daily

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Todd Davis - CEO Tavo Espinoza - CFO Paul Hadden - Senior Vice President of Investments and Business Development Karen Reeves - Senior Vice President of Investments and Head of Clinical Strategy Conference Call Participants Matt Hewitt - Craig-Hallum Douglas Miehm - RBC Capital Markets Lawrence Solow - CJS Operator Thank you for standing by. My name is Pam and I will be your conference operator today.

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Ligand Reports Second Quarter 2024 Financial Results

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. “We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December,” said Todd Davis, CEO of Liga.

Ligand Reports Second Quarter 2024 Financial Results

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report. Recent positive developments include new deals, regulatory successes, and raising 2024 guidance. A new deal of close to $200 million with Agenus and $100 million acquisition of APEIRON contribute to the positive outlook.

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027 Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal Phase 3 clinical trial results from a single-arm, baseline-controlled clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations currently being conducted under FDA's Breakthrough Therapy Designation and Fast Track Designation programs QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations, if approved Companies to host joint webcast on Wednesday, July 24 at 8:30am ET WAYNE, PA AND BOSTON, MA / ACCESSWIRE / July 24, 2024 / Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) (Pieris) today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on developing and commercializing Palvella's lead clinical product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), for the treatment of microcystic lymphatic malformations (microcystic LMs), cutaneous venous malformations, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Tuesday, August 6, 2024 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Conf.

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

5 Best Short-Term Stocks to Consider Investing In

Not every investor is in the market for the long haul. Some prefer short time frames and volatile stocks, looking to make a profit in days or weeks rather than years.

5 Best Short-Term Stocks to Consider Investing In

See News Rankings

Charts implemented using Lightweight Charts™